An ANOCEF Genomic and Transcriptomic Microarray Study of the Response to Irinotecan and Bevacizumab in Recurrent Glioblastomas
Table 2
Characteristics of the 33 patients from the Salpêtrière database for whom the impact of EGFR amplification and CDKN2A locus homozygous deletion was assessed.
Characteristics of the 33 patients of the independent dataset
Number of patients
33
Median age (years) at diagnosis (range)
59 (25–81)
Initial treatment (%)
RTCT (100%)
Median delay (months) between diagnosis and bev./iri. onset (range)